Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.

ABSTRACT:

Background

Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR) can stop therapy without relapsing. However, most information on treatment cessation was obtained from clinical trials with strict recruiting criteria.

Methods

We evaluated the outcome of 25 patients with CML that discontinued TKI therapy in our institute in real-world clinical practice.

Results

Of the 25 patients, 76% discontinued therapy in sustained deep molecular response (SDMR) and 24% were in unsustained DMR (UDMR). Discontinuation of therapy due to adverse effects was observ

SUBMITTER: Cerveira N 

PROVIDER: S-EPMC6292043 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature